

YUSUF N. HENRIQUES

V I S I O N A R Y



[Download Headshot](#)

Yusuf N. Henriques is the Founder and Chief Executive Officer of IndyGeneUS BIO, a pioneering BioFinTech company that holds exclusive access to the Missing 88%, the African, Indigenous and women's genomic data every major biobank has left out. Combined with its Clinico-Genomic Insight Engine™ (CGIE™) and sovereign infrastructure, that generates novel disease targets for all humanity across Cancer, Vision Loss, Cardiometabolic, Sickle Cell, Rare Diseases, Neurodegenerative, Veterans Health, Infectious Diseases and BioDefense.

A Jamaican-born immigrant and serial entrepreneur, Henriques has built his career at the intersection of financial innovation and health equity. His work challenges long-standing systems while introducing new frameworks that ensure precision medicine reflects the full diversity of humanity—not just a fraction of it. Often described as building “the BlackRock of genomics,” his leadership is anchored in both disruption and responsibility.

Henriques is a globally sought-after voice on precision health equity and Whole Genome Sequencing, with a particular focus on advancing outcomes for BIPOC communities. Whether on stage or in strategic advisory rooms, he brings clarity to complex scientific and economic conversations—bridging the gap between innovation and impact.

Before launching his ventures, Henriques established himself as a leading regulatory affairs expert. He began his federal career as Acting Branch Chief at the U.S. Food & Drug Administration (FDA), overseeing critical divisions including Ob/Gyn, Gastroenterology, and Urology within the Center for Devices and Radiological Health. He went on to serve as Director of Regulatory Affairs at SAIC, where he led compliance strategies for multi-site clinical trials, and as a lead regulatory scientist at Booz Allen Hamilton's Strategic Innovation Group.

His scientific leadership extended to the Department of Veterans Affairs, where he managed a \$45 million research portfolio focused on PTSD and Traumatic Brain Injury for the VA Cooperative Studies Program and the Department of Defense. During this time, he worked alongside renowned researcher Rachel Yehuda and secured exclusive rights to a groundbreaking PTSD genomic assay he developed—now being piloted across VA hospitals nationwide to address suicide rates among veterans and active-duty service members.

A graduate of Howard University, Henriques is currently pursuing a PhD in Biomedical Sciences, continuing to deepen his commitment to innovation grounded in scientific rigor. He leads a leadership team that reflects his values, with a C-suite comprised of fellow Howard alumni. Beyond the boardroom and the lab, Henriques is a devoted father of four daughters, an active voice on [LinkedIn](#), and a passionate soccer enthusiast.